BEIJING, Aug. 30 (Xinhua) -- Hainan Poly Pharmaceutical Co.,Ltd released an announcement on August 29 that its British customer confirmed approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the sales application for its new drug Ganciclovir sodium (API +preparation) for injection.
This approval by MHRA marks the Poly Pharmaceuticals’ qualification to sell the products in the UK market, and it will have a positive impact on the company’s further expansion into the European market. (Edited by Ma Xin, maxin11@xinhua.org)
A single purchase
